Академический Документы
Профессиональный Документы
Культура Документы
Index
Up/Down
Last
DJ Industrials
104.10
0.58%
18,120
S&P 500
12.90
0.61%
2,122
Nasdaq
36.97
0.72%
5,153
Russell 2000
7.65
0.59%
1,292
Economic Data
Lone piece of economic data today, May Existing-Home Sales rise 5.1% to 5.35M (above est.
5.26M), while April revised up to 5.09M from 5.04M; 5.1 months supply in May vs. 5.2 in April,
while inventory rose 3.2% to 2.29M homes; Median home price rose 7.9% YoY to $228,700
Commodities
WTI crude oil prices ended flattish, up about 7c to $59.68 per barrel, but was volatile, trading as
high as $60.30, and as low as $58.93. U.S. natural gas futures fell nearly 3%, off 8.3c to $2.733
mln btu on expectations for weaker demand in the latest weather forecast
Precious metals fell more than 1.5% as global equities jump on possible signs of progress in
Greek debt talks, which curbed safe-haven demand; gold ended lower by 1.5% to 1,184.10 an
ounce (recall hit around $1,205.50 hit last week after a dovish Federal Reserve message). The
absence of top consumer China, which was closed for holiday, also hurt gold prices
Currencies
The dollar index (DXY) was higher, reversing some earlier weakness, as currency markets are
closely watching the developments in Greece; the euro fell from an earlier high of 1.141 to trade
lower against the dollar under 1.1340; while the dollar advanced against the yen
Bond Market
Bond markets were generally weaker throughout the day, as yields extended upward to the
highs, catching up to the weakness in German Bunds on increased demand for risk. Longer dated
yields are over 10 bps higher with the 10-year hitting 2.36%; the 30-yr yield jumped to 3.15%,
while shorter-term yields popped (2-yr 0.65%, and 5-yr 1.66%). U.S. Treasuries prices tumbled on
optimism over a Greek deal and as stronger-than-expected U.S. existing home sales data
supported expectations of a September Federal Reserve rate hike
Macro
Up/Down
Last
WTI Crude
0.07
59.68
Brent
0.32
63.34
Gold
-17.80
1,184.10
EUR/USD
-0.001
1.1342
JPY/USD
0.70
123.41
10-Year Note
0.095
2.356%
Energy
Energy stocks among top sector gainers despite a drop in oil prices, as money rotating into
Energy, Financials, Healthcare, Transports; MLP space gets a lift after WMB news (see below)
MLPs; ETE confirmed it made a $48B bid for WMB which was rejected http://goo.gl/UfutRV (ETE
said its all-stock offer of 0.9358 shares per WMB share represented a 32% premium to the stock's
closing price of $48.34. WMB said on Sunday the unsolicited proposal had prompted it to launch
a review of strategic alternatives. ETE said its offer is contingent on the termination of Williams'
pending purchase of WPZ, which gathers, processes and transports natural gas
Utilities; PPL upgraded to Buy at Jefferies as believe the stock should trade at a group average
multiple given the recent spinoff of its unregulated business and the above average rate base
growth; defensive utilities as a whole was flattish
Financials
Large Cap and regional banks gain on pop in rates, overall market strength early, hopes for
Greece resolution; shares of C, BAC, WFC and JPM rise in large cap, while FITB, RF also gain
Insurance; MET upgraded to Outperform at RBC Capital citing belief that MetLife may launch
another share repurchase, as well as its contention that the company may be better positioned
than any other publicly traded life insurer to benefit from the rise in interest rates; ALL
downgraded to Sell at Citigroup in head to head comparison vs. PGR; PGR was also upgraded to
Outperform at Raymond James
REITs; HME to be acquired by Lone Star Funds for $75.23 per share http://goo.gl/s8PM6k ; UDR
in pact to buy six communities valued at $908M (from HME deal); shares of apartment REITs
really didnt move on the announced deal (EQR, PPS, AIV, NXRT)
Healthcare
Large Cap Pharma; M&A news leads group as CI rejected ANTMs $184 per share offer (deal
valued at $53.8B w/debt) http://goo.gl/azBS0q ; also, the WSJ reported AET made a takeover
proposal to HUM in the last few days but it wasnt clear how much Aetna indicated it would pay
http://goo.gl/SGspLr ; MRK positively mentioned in Barrons over the weekend
Biotech stocks again broadly higher, as the index touches another new all-time high earlier (the
NBI Biotech Index traded above 4,000 earlier for the first time in its existence, led by gains in
large as well as small-cap names); CELG, BIIB, AMGN, GILD up 1% early
CAR-T stocks; ZIOP downgraded at BMO Capital saying CAR-T and T-Cell receptor therapy
competitors are increasing their leads; KITE and BLUE in agreement to co-develop, cocommercialize second generation T cell receptor (TCR) product candidates to treat human
papillomavirus type 16 E6 (HPV-16 E6); Oppenheimer recommends owning QURE into two 2H15
readouts: Phase I/II data for AMT-060 (FIX gene) and Phase I/II data for AMT-110
Analyst calls; RDUS cut to hold at Maxim on valuation; RXDX new overweight at Piper; DPLO
reiterated Outperform and $50 tgt at RW Baird on attractive valuation; AKBA started with a buy
and $24 tgt at JMP Securities; MLV & Co analysts raise price target to $33 on SRNE
Hospital shares active; Barrons noted HCA may rise 20% if Supreme Court upholds tax subsidies
used by participants in federally run health exchanges under Affordable Care Act, Barrons
Follow-Up column said (also watch LPNT, CYH, UHS, THC) decision could come this week
Other movers; EPZM shares jump after objective responses were seen in 9 of 15 evaluable
patients with relapsed or refractory non-Hodgkin lymphoma treated with tazemetostat (EPZ6438) in Phase 1 study; TBIO rises on reports plans to launch liquid biopsy cancer test
Want a free trial to The Hammerstone Report 4x Daily ? Sign-up for a trial today at
www.thehammerstonereport.com
Please be sure to check out The Hammerstone Institutional Feed for News and Analysis for the
Informed Trader at www.hammerstoneinstitutional.com
***DISCLAIMER/LIMITATION OF LIABILITY: Hammerstone Inc. (the Report) provides information and data and does NOT provide any individual investment advice or money management
assistance and does NOT attempt to influence the sale or purchase of securities. The Report is intended for informational purposes only and does not claim to be actionable for investment
decisions. The information contained in the Report has been obtained from sources deemed to be reliable but is not represented to be complete, and it should not be relied upon as such. The
Report does not purport to be a complete analysis of any security, issuer, or industry and is not an offer or a solicitation of an offer t o buy or sell any securities. The Report is prepared for
general information purposes only and does not consider the specific investment objectives, financial situation, and particular needs of any individual subscriber, person, or entity